NANOG and cancer: It can be speculated that the downregulation of NANOG, OCT3/4 and SOX2 expression by PRI-2191, PRI-1907 or PRI-1917 might decrease the capacity of residual CSC to initiate cancer renewal after conventional chemotherapy.